Sonidegib Phosphate Patent Expiration

1. Odomzo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178563 SUN PHARM Compounds and compositions as hedgehog pathway modulators
Jul, 2029

(5 years from now)

US8063043 SUN PHARM Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
Sep, 2029

(5 years from now)

US10266523 SUN PHARM Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
Mar, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 24, 2020

NCE-1 date: 25 July, 2019

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of basal cell carcinoma


More Information on Dosage

ODOMZO family patents

Family Patents